Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519893 | 0.88 | FFAR1 (0.39) | FFAR1LMNACYP2C19 | |
| SCHEMBL1519634 | 0.87 | APP (0.44) | FFAR1GAAAPPDPP4DPP7 | |
| SCHEMBL1519753 | 0.87 | FFAR1 (0.44) | FFAR1 | |
| SCHEMBL5558097 | 0.86 | CYP2C9 (0.47) | FFAR1LMNAGAAAPPMEN1 | |
| SCHEMBL2878286 | 0.86 | CTSS (0.36) | CTSSCTSKALDH1A1MAPTCYP1A2 | |
| SCHEMBL6597704 | 0.84 | KCNA5 (0.36) | FFAR1LMNAHPGDALDH1A1AAK1 | |
| SCHEMBL17513198 | 0.82 | FFAR1 (0.41) | FFAR1CTSSCTSKLMNAHPGD | |
| SCHEMBL1519892 | 0.82 | FFAR1 (0.42) | FFAR1LMNAAPPHTTALDH1A1 | |
| SCHEMBL4923610 | 0.79 | AAK1 (0.38) | CTSSCTSKGAAAAK1MEN1 | |
| SCHEMBL1519857 | 0.78 | MEN1 (0.40) | FFAR1HPGDALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2487154-A1 | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| US-7897619-B2 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2173728-A2 | HETEROCYCLIC MODULATORS OF PKB | Amgen Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090275592-A1 | Heterocyclic modulators of PKB | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7488725-B2 | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods | BRISTOL-MYERS SQUIBB CO. (US) | 2009-02-10 | — | — | US | disclosed |
| WO-2009011880-A2 | HETEROCYCLIC MODULATORS OF PKB | AMGEN INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1943215-A2 | PYRROLIDINYL BETA-AMINO AMIDE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | Brystol-Myers Squibb Company (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053819-A2 | PYRROLIDINYL BETA-AMINO AMIDE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHODS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099913-A1 | To treat diabetes, especially type II diabetes including complications of diabetes; synergistic | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275592-A1 | Heterocyclic modulators of PKB | MTOR, PDK1, EIF4EBP1 | FFAR1 785/4885CTSS 3165/4885CTSK 2241/4885 |
| US-20070099913-A1 | To treat diabetes, especially type II diabetes including complications of diabetes; synergistic | GLP1R, GPR119, SLC5A2 | FFAR1 360/4885CTSS 3269/4885CTSK 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.